Financial Results : Saudi German Health logs SAR 174.9M profit in 9M 2024; Q3 at SAR 61.7M

Saudi German Health logs SAR 174.9M profit in 9M 2024; Q3 at SAR 61.7M

03/11/2024 Argaam Exclusive

View other reports

Middle East Healthcare Co. (Saudi German Health) reported a net profit of SAR 174.9 million for the first nine months of 2024, compared with SAR 143.7 million a year earlier.



Financials (M)

Item 9m 2023 9m 2024 Change‬
Revenues 1,933.36 2,133.94 10.4 %
Gross Income 720.45 831.82 15.5 %
Operating Income 255.35 339.24 32.9 %
Net Income 143.67 174.86 21.7 %
Average Shares 92.04 92.04 -
EPS (Riyals) 1.56 1.90 21.7 %

The profit was driven by an increase in patient flow, number of performed surgeries, and case mix, as well as a capital gain of SAR 19.6 million due to the sale of land in Riyadh.

 

The company reported a net profit of SAR 61.7 million in Q3 2024, up 16% from SAR 53.3 million in Q3 2023, spurred mainly by higher revenues.

 

Sequentially, Saudi German Health’s profit grew 0.9% from SAR 61.17 million in Q2 2024.



Current Quarter Comparison (M)

Compared With The
Item Q3 2023 Q3 2024 Change‬
Revenues 671.05 732.07 9.1 %
Gross Income 266.33 292.90 10.0 %
Operating Income 109.85 115.88 5.5 %
Net Income 53.30 61.74 15.8 %
Average Shares 92.04 92.04 -
EPS (Riyals) 0.58 0.67 15.8 %

Shareholders’ equity, no minority interest, stood at SAR 1.69 billion as of Sept. 30, 2024, up from SAR 1.51 billion a year earlier.

Kindly, you can view the full report by subscribing to the

The report contains the details of the financial statements, The most important financial indicators, Historical information, Charts, and Forecasts of experts.


Comments {{getCommentCount()}}

Be the first to comment

{{Comments.indexOf(comment)+1}}
{{comment.FollowersCount}}
{{comment.CommenterComments}}
loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.